AbbVie v Piramal: Sevoflurane “drop test” leaflet ruled promotional and missing mandatory information (AUTH/2815/12/15)

📅 8 March 2026 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/2815/12/15
PartiesAbbVie v Piramal Healthcare UK Ltd
MaterialLeaflet detailing a drop test of Sevoflurane Piramal screw-top glass bottles (ref MKT-SEV-025)
ProductSevoflurane (Sojourn Sevoflurane 100% Inhalation Vapour Liquid, UK PL 29595/0002)
Main issueLeaflet deemed promotional; missing cost, AE reporting statement, and date of preparation/last revision
Complaint received22 December 2015
Case completed6 May 2016
Applicable Code year2015
Breach clauses4.1, 4.9, 4.10, and 9.1
No breach clauses2
AppealNo appeal
SanctionsUndertaking received

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
📋

What happened

  • AbbVie complained about a Piramal leaflet describing a “drop test” of Sevoflurane Piramal screw-top glass bottles (ref MKT-SEV-025), used at a European conference and also used with customers and internally in the UK.
  • AbbVie alleged the leaflet was promotional and omitted mandatory items: cost, date drawn up, and the adverse event reporting statement; AbbVie also alleged failure to maintain high standards and that omission of AE reporting prejudiced patient safety (Clause 2).
  • Piramal argued the leaflet was not promotional because it focused on packaging robustness rather than clinical safety/efficacy, and said it had been withdrawn from use/external distribution in November 2015 (though this was not made clear during inter-company dialogue).
  • The Panel considered that packaging is part of the medicine and could influence choice; therefore claims about packaging (including reference to a 5-year shelf life) fell within promotion.
⚖️

Outcome

  • The leaflet was ruled to be promotional and therefore subject to the Code.
  • Breach ruled for missing cost information (as part of prescribing information requirements): Clause 4.1.
  • Breach ruled for missing adverse event reporting statement: Clause 4.9.
  • Breach ruled for missing date of preparation/last revision: Clause 4.10.
  • Breach ruled for failure to maintain high standards: Clause 9.1.
  • No breach of Clause 2 (Panel considered an additional Clause 2 ruling disproportionate in the circumstances).
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free